Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...

On Monday, Corcept Therapeutics Incorporated (CORT) stock saw a modest uptick, ending the day at $50.06 which represents a slight increase of $2.44 or 5.12% from the prior close of $47.62. The stock ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Corcept Therapeutics (CORT – Research Report). The ...

Corcept's Phase 3 GRADIENT trial for relacorilant has missed its primary endpoint – the improvement in SBP for Cushing's ...

The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 27 cents per share. The drug developer posted revenue of $182.5 million in the period, which also beat ...

List today: American Assets Trust, Inc. AAT: This self-administered real estate investment trust has seen the Zacks Consensus ...

Corcept Therapeutics Incorporated has a 52-week low of $20.84 and a 52-week high of $50.07. The company has a market cap of $4.88 billion, a P/E ratio of 44.24 and a beta of 0.46.

Good day and thank you for standing by. Welcome to the Corcept Therapeutics Conference Call. At this time, all participants are in listen-only mode. After speaker's presentation, there will be a ...

On Tuesday, Corcept Therapeutics Incorporated (CORT) stock saw a decline, ending the day at $48.21 which represents a decrease of $-0.13 or -0.27% from the prior close of $48.34. The stock opened at ...

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.28 per share a year ago.